Australian researchers lead world in successful trial of new cancer treatment
3 June 2021
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Relatlimab is the first immunotherapy treatment to target LAG-3, a protein in immune cells which reinvigorates and enhances the tumour fighting response.
Immune checkpoint inhibitors targeting the CTLA-4 and PD-1 proteins have revolutionised treatment of advanced melanoma over the past seven years. These treatments are most effective when used in combination, but this tends to increase their toxicity. Some 50% of patients either do not respond, or develop resistance, to these treatments and therefore it is vital that new treatments are developed.
Melanoma Institute Australia (MIA) Co-Medical Director, Professor Georgina Long AO of The University of Sydney, said the successful trial of relatlimab, targeting the LAG-3 protein, makes it a critical new weapon in the fight to save all lives from melanoma.
‘This drug gives us a third immune checkpoint inhibitor to add to the treatment toolkit which may be the difference between survival or not for melanoma patients around the world,’ Professor Long said.
‘Immunotherapy harnesses the body’s own immune system to fight the cancer cells and having a third immune checkpoint inhibitor means we can potentially make inroads in saving the 50% of advanced melanoma patients who don’t respond to current treatments.
‘Australian researchers and patients were critical to trialling this new treatment which has very real potential to also extend to other cancers.’
The findings from the RELATIVITY-047 trial will be presented this weekend at the American Society of Clinical Oncology (ASCO) Annual Meeting. Professor Georgina Long is senior lead author for the international trial and MIA was a leading contributor of patients for the study.
Results showed that in previously untreated advanced melanoma patients, combining relatlimab with nivolumab (an immune checkpoint inhibitor targeting the PD-1 protein) doubled the progression free survival time compared to the use of nivolumab alone (10.1 vs 4.6 months respectively).
At one year, almost 50% of patients on the combination therapy had no disease progression, whereas nearly two-thirds of patients on the single therapy had progressed. Importantly, the combined therapy was also far less toxic to patients.
‘Immunotherapy has already transformed the treatment of melanoma and other cancers, with anti-PD-1 therapies leading the way,’ Professor Long said.
‘This new immune checkpoint inhibitor that targets LAG-3, and its proven effectiveness when used in combination, improves outcomes for melanoma patients even further and will likely impact cancer treatment globally.’
Melanoma Institute Australia is affiliated with The University of Sydney and Professor Long co-leads the Translational Research Group at the Charles Perkins Centre.Watch Prof Georgina Long AO and melanoma survivor Andrew Bennett when the breakthrough was announced on Channel 9 news:
Media - for more information, please contact:
m: 0412 798 990
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
Research achievements by MIA were celebrated at the annual Sydney Medical School recently.
In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.
Professor’s Long and Scolyer are well known in the academic community and beloved by their patients. But we wanted to get to know our new Conjoint Medical Directors a little more and hear their plans on making an impact on melanoma.
Wyong Rugby League Club Group has joined forces with Melanoma Institute Australia to help end melanoma for future generations.
Melanoma research has reached a milestone with the 10,000th patient giving their permission for their blood and tissue samples to be used in the world’s largest melanoma biospecimen bank.
MIA's researchers and clinicians are in Seattle, USA, today sharing their research findings at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium.
Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.
Meet Georgia, our Clinica Nurse Consultant who provides vital care and education for patients throughout their treatment.
Australia, we need to talk. This week’s dramatic episodes of Married At First Sight have highlighted a tragedy which is ripping Australian families apart. Yet no one is talking about it.
To celebrate International Women's Day 2017, MIA shares how some of the women who inspire the way we work every day, are showing their commitment to accelerate gender parity.
We welcome Mr Grant King to the position of Chairman of the Board of Melanoma Institute Australia, following the retirement of Mr Reg Richardson AM who led the organisation for 10 years.
Congratulations to PhD Student, Tuba Nur Gide who was awarded a NSW National Council of Women Australia Day Award for her PhD research work.
Melanoma Institute Australia, is joining forces with the Wollongong Wolves Football Club in the battle to reduce Australia’s melanoma rates.